QuidelOrtho Q4 GAAP loss $2.28/sh; FY2024 rev $2.78B; guides FY25 rev $2.60-$2.81B, adj EBITDA margin 22%

QuidelOrtho Corp

2024-FY EPS reported -$30.54 revenue$2,782,900,000

Q4 GAAP diluted loss per share $2.28 vs EPS $0.10 prior year; adjusted EPS $0.63 vs $1.17.
Q4 revenue $708M, down 5% YoY; non-respiratory flat; Labs revenue grew 4% ex-COVID and non-core.
Full-year GAAP net loss $2.03B includes $1.82B goodwill impairment; adjusted EBITDA $543M, margin 19.5%.
FY2025 guidance: revenue $2.60-$2.81B, adjusted EBITDA $575-$615M, adjusted diluted EPS $2.07-$2.57.
Company cites cost-savings initiatives targeting incremental margin improvement and 22% adjusted EBITDA margin in 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.